A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Weitere Versionen anzeigen (1)

OBJECTIVES: This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. DATA SOURCES: Electronic databases were search...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Chen, Y, Jobanputra, P, Barton, P, Jowett, S, Bryan, S, Clark, W, Fry-Smith, A, Burls, A
Format:	Journal article
Sprache:	English
Veröffentlicht:	2006

Ähnliche Einträge

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
von: Chen, Y, et al.
Veröffentlicht: (2006)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
von: Jobanputra, P, et al.
Veröffentlicht: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
von: Jobanputra, P, et al.
Veröffentlicht: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
von: P. Jobanputra, et al.
Veröffentlicht: (2002-01-01)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
von: K Malottki, et al.
Veröffentlicht: (2011-03-01)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
von: Martínez-Pérez Rosalía, et al.
Veröffentlicht: (2011-11-01)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
von: M Rodgers, et al.
Veröffentlicht: (2011-02-01)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
von: Clark, W, et al.
Veröffentlicht: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
von: Clark, W, et al.
Veröffentlicht: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
von: Clark, W, et al.
Veröffentlicht: (2004)

Etanercept for the treatment of rheumatoid arthritis.
von: Lethaby, A, et al.
Veröffentlicht: (2013)

Etanercept for the treatment of rheumatoid arthritis.
von: Blumenauer, B, et al.
Veröffentlicht: (2003)

Etanercept for the treatment of rheumatoid arthritis
von: Blumenauer, B, et al.
Veröffentlicht: (2004)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
von: Henry Alistair I, et al.
Veröffentlicht: (2011-11-01)

Infliximab for the treatment of rheumatoid arthritis.
von: Blumenauer, B, et al.
Veröffentlicht: (2002)

Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
von: Stephanie F. Ling, et al.
Veröffentlicht: (2024-05-01)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
von: Cummins, C, et al.
Veröffentlicht: (2002)

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
von: Cummins, C, et al.
Veröffentlicht: (2002)

Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis
von: Fisher, B, et al.
Veröffentlicht: (2016)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
von: Chen HH, et al.
Veröffentlicht: (2016-02-01)

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
von: Areej S. Albahdal, et al.
Veröffentlicht: (2024-02-01)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
von: Barton, P, et al.
Veröffentlicht: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
von: Barton, P, et al.
Veröffentlicht: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction
von: Barton, P, et al.
Veröffentlicht: (2004)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.
von: Ignacio Ortea, et al.
Veröffentlicht: (2016-01-01)

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
von: Clark, W, et al.
Veröffentlicht: (2003)

Systemic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease
von: Clark, W, et al.
Veröffentlicht: (2003)

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
von: Clark, W, et al.
Veröffentlicht: (2003)

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease
von: W. Clark, et al.
Veröffentlicht: (2003-01-01)

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
von: N Woolacott, et al.
Veröffentlicht: (2006-09-01)

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation
von: Jonathan Shepherd, et al.
Veröffentlicht: (2016-04-01)

Infliximab in the therapy of rheumatoid arthritis
von: G. V. Lukina, et al.
Veröffentlicht: (2016-05-01)

Etanercept plus sulfasalazine: added value in rheumatoid arthritis?
von: Fisher, B, et al.
Veröffentlicht: (2007)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
von: Joao Goncalves, et al.
Veröffentlicht: (2019-12-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
von: Ruiz Garcia, V, et al.
Veröffentlicht: (2011)

Adalimumab in the treatment of early rheumatoid arthritis
von: Y A Sigidin, et al.
Veröffentlicht: (2008-04-01)

Infliximab and methotrexate in the treatment of rheumatoid arthritis
von: Lipsky, P, et al.
Veröffentlicht: (2000)

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
von: Jobanputra, P, et al.
Veröffentlicht: (2004)

Quality of life of patients with rheumatoid arthritis receiving etanercept
von: V N Amirdzanova, et al.
Veröffentlicht: (2009-08-01)

EFFECTIVENESS AND SAFETY OF INFLIXIMAB IN PATIENTS WITH EARLY JUVENILE RHEUMATOID ARTHRITIS
von: E.I. Alexeeva, et al.
Veröffentlicht: (2009-07-01)